RAPT Therapeutics, Inc. (RAPT)
NASDAQ: RAPT · Real-Time Price · USD
1.140
0.00 (0.00%)
At close: Jan 31, 2025, 4:00 PM
1.145
+0.005 (0.44%)
After-hours: Jan 31, 2025, 4:00 PM EST
RAPT Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
131
Market Cap
153.85M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.88B |
Abbott Laboratories | 41.95B |
RAPT News
- 23 days ago - RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 26 days ago - RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors - GlobeNewsWire
- 5 weeks ago - RAPT Therapeutics Announces $150 Million Private Placement - GlobeNewsWire
- 2 months ago - Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury - Benzinga
- 6 months ago - RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus - Seeking Alpha
- 9 months ago - Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Renovaro (NASDAQ:RENB) - Benzinga
- 9 months ago - RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity - Seeking Alpha
- 9 months ago - RAPT Therapeutics Reports First Quarter 2024 Financial Results - GlobeNewsWire